AR053446A1 - Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancer - Google Patents
Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancerInfo
- Publication number
- AR053446A1 AR053446A1 ARP060100970A ARP060100970A AR053446A1 AR 053446 A1 AR053446 A1 AR 053446A1 AR P060100970 A ARP060100970 A AR P060100970A AR P060100970 A ARP060100970 A AR P060100970A AR 053446 A1 AR053446 A1 AR 053446A1
- Authority
- AR
- Argentina
- Prior art keywords
- chosen
- group
- lower alkyl
- lower alkoxy
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001093 anti-cancer Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000003545 alkoxy group Chemical group 0.000 abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- -1 [1,4] diazepanyl Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- PXKMKUUCUJOWFO-UHFFFAOYSA-N morpholine;piperidine;pyrrolidine Chemical compound C1CCNC1.C1CCNCC1.C1COCCN1 PXKMKUUCUJOWFO-UHFFFAOYSA-N 0.000 abstract 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos inhiben la interaccion MDM2-p53 y que, como tales, los compuestos tendrán una actividad celular anti- hiperproliferativa. Composicion, uso y proceso. Reivindicacion 1: Un compuesto de formula (1), y las sales y ésteres farmacéuticamente aceptables del mismo; en la que X1 se elige entre el grupo formado por: alcoxi inferior; alcoxi inferior sustituido por trifluorometilo o fluor; X2 y X3 con independencia entre sí se eligen entre el grupo formado por: hidrogeno; halogeno; ciano; alquilo inferior; alcoxi inferior; piperidinilo; -NX4X5; -SO2NX4X5; -C(O) NX4X5; -C(O)X6; -SOX6, -SO2X6; -NC(O)-alcoxi inferior; -C:::C-X7; con la condicion de que X2 y X3 no sean ambos hidrogeno, alquilo inferior ni alcoxi inferior; con la condicion de que cuando X2 o X3 es hidrogeno, el otro no sea alquilo inferior, alcoxi inferior ni halogeno; X2 y X3 pueden tomarse juntos para formar un anillo elegido entre anillos insaturados de 5 a 7 eslabones, y anillos insaturados de 5 a 7 eslabones que contienen por lo menos un heteroátomo elegido entre S, N y O; X4 y X5 con independencia entre sí se eligen entre el grupo formado por: hidrogeno; alquilo inferior; cicloalquilo; alcoxi inferior; alquilo inferior sustituido por alcoxi inferior; -SO2-alquilo inferior; -C(O)-piperazinil-3-ona; X6 se elige entre el grupo formado por: alquilo inferior; morfolina; piperidina; pirrolidina; X7 se elige entre el grupo formado por: hidrogeno; alquilo inferior; trifluorometilo; Y1 e Y2 con independencia entre sí se eligen entre el grupo formado por: halogeno; acetileno; R se elige entre el grupo formado por: alcoxi inferior; piperidinilo sustituido por un heterociclo de cinco o seis eslabones; piperidinilo sustituido por hidroxi, - CH2OH o -C(O)NH2; piperazinilo sustituido por R1; [1,4] diazepanilo sustituido por R1; R1 puede ser uno o dos sustituyentes elegidos entre el grupo formado por: hidrogeno; oxo; alquilo inferior sustituido por R2; -C(O)R3; -SO2-alquilo inferior; -SO2- heterociclilo de cinco eslabones; R2 se elige entre el grupo formado por: -SO2-alquilo inferior; hidroxi; alcoxi inferior; trifluorometilo; -NH-SO2-alquilo inferior; -NH-C(O)-alquilo inferior; -C(O)-alquilo inferior; -ciano; -C(O)R4; R3 se elige entre el grupo formado por: heterociclilo; alquilo inferior; alquenilo inferior; alquilo inferior sustituido por alcoxi inferior o un heterociclilo de cinco o seis eslabones; alcoxi inferior; cicloalquilo; R4 se elige entre el grupo formado por: hidroxi; alcoxi inferior; morfolina; piperidina; pirrolidina; aziridina; 4-acetil-piperazinilo; -NR5R6; R5 y R6 con independencia entre sí se eligen entre el grupo formado por: hidrogeno; alquilo inferior; alquilo inferior sustituido por alcoxi inferior o ciano; alcoxi inferior; y cicloalquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66251605P | 2005-03-16 | 2005-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053446A1 true AR053446A1 (es) | 2007-05-09 |
Family
ID=36572145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100970A AR053446A1 (es) | 2005-03-16 | 2006-03-14 | Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7579368B2 (es) |
| EP (1) | EP1861376A1 (es) |
| JP (1) | JP4955646B2 (es) |
| KR (2) | KR20100031783A (es) |
| CN (1) | CN101155784A (es) |
| AR (1) | AR053446A1 (es) |
| AU (1) | AU2006224765B2 (es) |
| BR (1) | BRPI0607445A2 (es) |
| CA (1) | CA2599476A1 (es) |
| IL (1) | IL185381A0 (es) |
| MX (1) | MX2007011151A (es) |
| NO (1) | NO20074391L (es) |
| RU (1) | RU2411238C2 (es) |
| TW (1) | TWI314552B (es) |
| WO (1) | WO2006097261A1 (es) |
| ZA (1) | ZA200707653B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101605798A (zh) | 2006-12-14 | 2009-12-16 | 第一三共株式会社 | 咪唑并噻唑衍生物 |
| JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| CN101906085B (zh) * | 2009-06-04 | 2013-12-11 | 天津药物研究院 | 治疗心脑血管疾病的化合物、组合物、制备方法及用途 |
| KR20120050492A (ko) * | 2009-08-26 | 2012-05-18 | 노파르티스 아게 | 테트라-치환된 헤테로아릴 화합물 및 ｍｄｍ2 및/또는 ｍｄｍ4 조절제로서의 그의 용도 |
| US10159669B2 (en) * | 2010-03-02 | 2018-12-25 | Ian H. Chan | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| ES2685175T3 (es) | 2010-09-30 | 2018-10-05 | St. Jude Children's Research Hospital | Imidazoles sustituidos con arilo |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| KR20150058430A (ko) * | 2012-09-19 | 2015-05-28 | 바스프 에스이 | 아세틸렌 가교 링커 및 그로부터 제조된 금속-유기 골격체(MOFs) |
| WO2014082889A1 (en) * | 2012-11-28 | 2014-06-05 | F. Hoffmann-La Roche Ag | Novel imidazolines as dual inhibitors of mdm2 and mdmx |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| MX374513B (es) | 2013-03-14 | 2025-03-06 | Amgen Inc | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| JP6473133B2 (ja) * | 2013-03-15 | 2019-02-20 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの共有結合性阻害剤 |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| JP6537118B2 (ja) | 2013-08-07 | 2019-07-03 | 東洋合成工業株式会社 | 化学増幅フォトレジスト組成物及び装置の製造方法 |
| CN104418867B (zh) * | 2013-08-26 | 2016-12-28 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途 |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| WO2015184383A1 (en) * | 2014-05-29 | 2015-12-03 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles and methods of making and using same |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| MX2017013275A (es) | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos. |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| JP7001614B2 (ja) | 2016-04-06 | 2022-02-03 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | リガンド依存性の標的タンパク質分解のための単官能性中間体 |
| JP7037500B2 (ja) | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| US11207312B2 (en) | 2017-07-17 | 2021-12-28 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors and methods of use thereof |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| US11046703B2 (en) | 2018-10-08 | 2021-06-29 | The Regents Of The University Of Michigan | Small molecule MDM2 protein degraders |
| CA3171258A1 (en) | 2020-03-19 | 2021-09-23 | Nan JI | Mdm2 degraders and uses thereof |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9702030A (es) * | 1994-09-26 | 1997-06-28 | Shionogi & Co | Derivado de imidazol. |
| ES2301717T3 (es) | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores. |
| US7425638B2 (en) * | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| RU2319696C2 (ru) * | 2003-06-17 | 2008-03-20 | Ф.Хоффманн-Ля Рош Аг | Цис-2, 4, 5-триарил-имидазолины |
| DE602005011132D1 (de) * | 2004-05-18 | 2009-01-02 | Hoffmann La Roche | Neuartige cis-imidazoline |
| US7893278B2 (en) * | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
-
2006
- 2006-03-13 KR KR1020107004985A patent/KR20100031783A/ko not_active Withdrawn
- 2006-03-13 RU RU2007137987/04A patent/RU2411238C2/ru not_active IP Right Cessation
- 2006-03-13 JP JP2008501211A patent/JP4955646B2/ja not_active Expired - Fee Related
- 2006-03-13 WO PCT/EP2006/002282 patent/WO2006097261A1/en not_active Ceased
- 2006-03-13 MX MX2007011151A patent/MX2007011151A/es active IP Right Grant
- 2006-03-13 TW TW095108346A patent/TWI314552B/zh not_active IP Right Cessation
- 2006-03-13 KR KR1020077021160A patent/KR101139263B1/ko not_active Expired - Fee Related
- 2006-03-13 AU AU2006224765A patent/AU2006224765B2/en not_active Ceased
- 2006-03-13 CN CNA2006800083402A patent/CN101155784A/zh active Pending
- 2006-03-13 CA CA002599476A patent/CA2599476A1/en not_active Abandoned
- 2006-03-13 EP EP06707535A patent/EP1861376A1/en not_active Ceased
- 2006-03-13 BR BRPI0607445-6A patent/BRPI0607445A2/pt not_active IP Right Cessation
- 2006-03-13 US US11/374,407 patent/US7579368B2/en not_active Expired - Fee Related
- 2006-03-14 AR ARP060100970A patent/AR053446A1/es not_active Application Discontinuation
-
2007
- 2007-08-20 IL IL185381A patent/IL185381A0/en unknown
- 2007-08-29 NO NO20074391A patent/NO20074391L/no not_active Application Discontinuation
- 2007-09-05 ZA ZA2007/07653A patent/ZA200707653B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200700393A (en) | 2007-01-01 |
| KR20100031783A (ko) | 2010-03-24 |
| EP1861376A1 (en) | 2007-12-05 |
| US20060211693A1 (en) | 2006-09-21 |
| IL185381A0 (en) | 2008-02-09 |
| RU2411238C2 (ru) | 2011-02-10 |
| ZA200707653B (en) | 2013-02-27 |
| BRPI0607445A2 (pt) | 2009-09-01 |
| US7579368B2 (en) | 2009-08-25 |
| MX2007011151A (es) | 2007-10-17 |
| WO2006097261A1 (en) | 2006-09-21 |
| AU2006224765B2 (en) | 2012-02-09 |
| CA2599476A1 (en) | 2006-09-21 |
| KR101139263B1 (ko) | 2012-05-16 |
| TWI314552B (en) | 2009-09-11 |
| JP4955646B2 (ja) | 2012-06-20 |
| JP2008533073A (ja) | 2008-08-21 |
| CN101155784A (zh) | 2008-04-02 |
| KR20070107129A (ko) | 2007-11-06 |
| RU2007137987A (ru) | 2009-04-27 |
| AU2006224765A1 (en) | 2006-09-21 |
| NO20074391L (no) | 2007-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053446A1 (es) | Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancer | |
| AR049545A1 (es) | Cis-imidazolinas | |
| AR059040A1 (es) | Cis-4, 5- biaril-2- heterociclico imidazolinas como inhibidores de la mdm 2 | |
| NO20052469L (no) | Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2. | |
| PE20141110A1 (es) | Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos | |
| AR078976A1 (es) | Inhibidores heterociclicos de la proteina ns5a codificada por el virus de la hepatitis c(vhc), composiciones farmaceuticas que los comprenden y uso de los mismos para tratar infecciones por vhc | |
| AR042095A1 (es) | Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih | |
| ES2531410T3 (es) | Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintasa quinasa 3 | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| PA8607001A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| PE20070519A1 (es) | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR078606A1 (es) | Derivados de piperidina para prevenir y/o tratar trastornos degenerativos del sistema nervioso central | |
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
| CO2022017790A2 (es) | Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos | |
| ES2075672T3 (es) | Amidinocompuestos, su fabricacion y uso como medicamento. | |
| PE20050726A1 (es) | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos | |
| UY27232A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
| PE20061144A1 (es) | DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs) | |
| PE20070124A1 (es) | Derivados de heteroaril para tratar virus | |
| AR024494A1 (es) | Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos | |
| ES2038766T3 (es) | 4-aril-5-carbamoil-1,4-dihidropiridinas. | |
| AR041481A1 (es) | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |